PDK4 and prostate neoplasm: Together, these data suggest that targeting of PDK4, specifically in a treatment-damaged TME, which harbors a considerable number of senescent cells, can substantially promote tumor regression in chemotherapeutic settings, a process independent of androgen regulation or AR signaling of prostate tumors per se.